Get startedLog in
    Picture of Contineum Therapeutics logo

    CTNM — Contineum Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapNeutral
    All News

    Brief: Contineum Therapeutics Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis

    Picture of Contineum Therapeutics logoContineum Therapeutics
    20/11/2025 21:43
    Nov 20 (Reuters) - Contineum Therapeutics Inc CTNM.O:

CONTINEUM THERAPEUTICS REPORTS TOPLINE DATA FROM ITS PHASE 2 PIPE-307 VISTA TRIAL FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)

CONTINEUM THERAPEUTICS INC - TRIAL DID NOT MEET PRIMARY OR SECONDARY EFFICACY ENDPOINTS

CONTINEUM THERAPEUTICS INC - PIPE-307 SHOWS NO SIGNIFICANT CHANGE IN LCLA

CONTINEUM THERAPEUTICS INC - PIPE-307 SHOWS ACCEPTABLE SAFETY AND TOLERABILITY

Source text: ID:nBw6GBK72a

Further company coverage: CTNM.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Contineum Therapeutics

    See all news